查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1540808

2024-2032 年按作用机制、药物类别、活性谱、给药途径、最终用户和地区分類的抗生素市场报告

Antibiotics Market Report by Action Mechanism, Drug Class, Spectrum of Activity, Route of Administration, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

2023年全球抗生素市场规模达514亿IMARC Group。肺炎、结核病和其他传染病在个体中的盛行率不断上升，抗菌素抗药性（AMR）的发生率不断上升，以及生物技术和药物发现技术的进步是推动市场的一些主要因素。

抗生素是一类用于治疗细菌感染的药物。它们以多种形式广泛存在，例如丸剂、胶囊、注射剂、乳膏和软膏。它们要么杀死细菌，要么抑制其生长，以有效消除感染。它们针对细菌细胞内的特定机製或结构，干扰其重要功能并阻止其繁殖。除此之外，它们还有助于增强个体的免疫系统。因此，抗生素被用来治疗各种疾病，例如泌尿道感染（UTI）、呼吸道感染、皮肤感染和某些个别性传染病。

目前，世界各地群众中多种慢性病的盛行率不断上升，推动了市场的成长。此外，抗生素透过全球线上和线下商店的广泛供应正在加强市场的成长。除此之外，对局部抗生素的需求不断增长，因为它们可以最大限度地降低个人手术部位感染的风险，并且正在对市场产生积极影响。此外，为了保障动物健康和福利以及支持食品安全，畜牧业中越来越多地使用抗生素，这也促进了市场的成长。与此一致的是，老年人口对抗生素的需求不断增长正在支持市场的成长。此外，消费者对预防保健措施的认识不断增强正在推动市场的成长。

抗生素市场趋势/驱动因素：

传染病病率上升

全球范围内，肺炎、结核、泌尿道感染（UTI）、胃肠道感染和败血症等传染病的盛行率呈上升趋势。由于卫生设施不足，导致细菌感染传播，人们越来越多地遭受这些疾病的困扰。此外，抗药性细菌的出现也增加了对抗生素的需求。对有助于治疗这些感染的有效抗生素的需求不断增加。抗生素是专门针对和消除细菌感染而设计的。它们能有效杀死体内的细菌并促进个体癒合。此外，抗生素是在医疗保健专业人员的指导下使用的，以优化患者的治疗效果。

抗菌素抗药性 (AMR) 的发生率增加

全球抗生素抗药性（AMR）的发生率不断上升，推动了抗生素市场的发展。当细菌、病毒、寄生虫或真菌进化并对治疗它们的药物产生抗药性时，就会发生抗菌素抗药性。它降低了抗生素的有效性，导致感染时间更长、更严重、医疗费用增加以及个人死亡率高。抗生素的过度使用和滥用会导致抗药性细菌的产生，从而降低传统抗生素的效果。此外，多重抗药性菌株，如抗甲氧西林金黄色葡萄球菌（MRSA）和抗碳青霉烯类肠桿菌（CRE）也更为常见。这就需要开发新的抗生素或替代疗法来对抗这些抗药性菌株。

抗生素技术进步

生物技术、分子生物学和药物发现技术的创新有助于提高抗生素开发的效率和有效性。基因组学和高通量筛选可以识别潜在的药物标靶并筛选大型化合物库。此外，电脑辅助药物设计可以预测药物疗效并优化候选抗生素。这些技术进步简化了抗生素的发现过程，并减少了与传统方法相关的时间和成本。此外，诊断技术的进步，例如快速病原体识别和药物敏感性测试，有助于适当的抗生素选择和处方，从而改善患者的治疗效果。此外，技术进步有助于开发新的、更有效的抗生素来解决传染病和抗菌素抗药性。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球抗生素市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按行动机制

  • 细胞壁合成抑制剂
    • 市场趋势
    • 市场预测
  • 蛋白质合成抑制剂
    • 市场趋势
    • 市场预测
  • DNA合成抑制剂
    • 市场趋势
    • 市场预测
  • RNA合成抑制剂
    • 市场趋势
    • 市场预测
  • 分枝菌酸抑制剂
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依药物类别

  • 头孢菌素
    • 市场趋势
    • 市场预测
  • 青霉素
    • 市场趋势
    • 市场预测
  • 氟喹诺酮类
    • 市场趋势
    • 市场预测
  • 大环内酯
    • 市场趋势
    • 市场预测
  • 碳青霉烯类
    • 市场趋势
    • 市场预测
  • 氨基糖苷类
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依活动范围

  • 广效抗生素
    • 市场趋势
    • 市场预测
  • 窄谱抗生素
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：依管理途径

  • 口服
    • 市场趋势
    • 市场预测
  • 注射用
    • 市场趋势
    • 市场预测
  • 专题
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：依最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 专科诊所
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 12 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 13 章：价值链分析

第 14 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 15 章：价格分析

第16章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Allergan Plc (AbbVie Inc.)
    • Basilea Pharmaceutica AG
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Melinta Therapeutics
    • Merck & Co. Inc.
    • Nabriva Therapeutics Plc
    • Paratek Pharmaceuticals Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Spero Therapeutics
    • Tetraphase Pharmaceuticals
Product Code: SR112024A3569

The global antibiotics market size reached US$ 51.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 70.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.5% during 2024-2032. The growing prevalence of pneumonia, tuberculosis, and other infectious diseases among individuals, rising occurrence of antimicrobial resistance (AMR), and technological advancements in biotechnology and drug discovery techniques are some of the major factors propelling the market.

Antibiotics are a class of medications that are used to treat bacterial infections. They are widely available in various forms, such as pills, capsules, injections, creams, and ointments. They either kill bacteria or inhibit their growth to effectively eliminate infections. They target specific mechanisms or structures within bacterial cells and interfering with their vital functions and preventing their reproduction. Besides this, they assist in enhancing the immune system of individuals. As a result, antibiotics are utilized to treat various diseases, such as urinary tract infections (UTI), respiratory tract infections, skin infections, and certain sexually transmitted diseases among individuals.

At present, the increasing prevalence of numerous chronic diseases among the masses around the world is contributing to the growth of the market. Additionally, the wide availability of antibiotics through online and offline stores across the globe is strengthening the growth of the market. Apart from this, the growing demand for topical antibiotics, as they minimize the risk of surgical site infections among individuals, is positively influencing the market. Moreover, the increasing employment of antibiotics in livestock farming to safeguard animal health and welfare and support food safety is bolstering the growth of the market. In line with this, the rising demand for antibiotics among the geriatric population is supporting the growth of the market. Furthermore, the increasing consumer awareness about preventive healthcare measures is impelling the growth of the market.

Antibiotics Market Trends/Drivers:

Rising prevalence of infectious diseases

There is a rise in the prevalence of infectious diseases, such as pneumonia, tuberculosis, urinary tract infections (UTI), gastrointestinal infections, and sepsis, among the masses across the globe. People are increasingly suffering from these diseases due to inadequate sanitation, which contributes to the spread of bacterial infections. In addition, the emergence of drug-resistant bacteria is increasing the demand for antibiotics. There is a rise in the demand for effective antibiotics that assist in treating these infections. Antibiotics are specifically designed to target and eliminate bacterial infections. They effectively kill bacteria in the body and promote healing among individuals. Furthermore, antibiotics are used under the guidance of healthcare professionals to optimize patient outcomes.

Increasing occurrence of antimicrobial resistance (AMR)

There is a rise in the occurrence of antimicrobial resistance (AMR) across the globe, which is driving the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi evolve and become resistant to the drugs used to treat them. It reduces the effectiveness of antibiotics and causes longer and more severe infections, increased healthcare costs, and high mortality rates among individuals. Overuse and misuse of antibiotics are contributing to the development of drug-resistant bacteria, which makes traditional antibiotics less effective. In addition, multidrug-resistant strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more prevalent. This necessitates the development of new antibiotics or alternative treatments to combat these resistant strains.

Technological advancements in antibiotics

Innovations in biotechnology, molecular biology, and drug discovery techniques assist in improving the efficiency and effectiveness of antibiotic development. Genomics and high-throughput screening allow the identification of potential drug targets and the screening of large compound libraries. Moreover, computer-aided drug design enables the prediction of drug efficacy and optimizes antibiotic candidates. These technological advancements streamline the antibiotic discovery process and reduce the time and costs associated with traditional methods. Additionally, advancements in diagnostic techniques, such as rapid pathogen identification and susceptibility testing, assist in appropriate antibiotic selection and prescribing that provides enhanced patient outcomes. Furthermore, technological advancements aid in the development of new and more potent antibiotics to address infectious diseases and antimicrobial resistance.

Antibiotics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global antibiotics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on action mechanism, drug class, spectrum of activity, route of administration and end user.

Breakup by Action Mechanism:

Cell Wall Synthesis Inhibitors

Protein Synthesis Inhibitors

DNA Synthesis Inhibitors

RNA Synthesis Inhibitors

Mycolic Acid Inhibitors

Others

Cell wall synthesis inhibitors represent the largest market segment

The report has provided a detailed breakup and analysis of the market based on the action mechanism. This includes cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, mycolic acid inhibitors, and others. According to the report, cell wall synthesis represented the largest segment.

Cell wall synthesis is a class of antibiotics that target the bacterial cell wall. These antibiotics interfere with the process of cell wall synthesis, which causes cell wall damage and eventual bacterial death. In addition, penicillin, cephalosporins, and carbapenems are some of the cell wall synthesis inhibitors. They work by inhibiting enzymes called penicillin-binding proteins (PBPs) that are involved in the cross-linking of peptidoglycan chains. Moreover, cell wall synthesis inhibitors are particularly effective against gram-positive bacteria due to their thicker peptidoglycan layer, which provides a greater target for disruption.

Breakup by Drug Class:

Cephalosporin

Penicillin

Fluoroquinolone

Macrolide

Carbapenem

Aminoglycoside

Others

Penicillin accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes cephalosporin, penicillin, fluoroquinolone, macrolide, carbapenem, aminoglycoside, and others. According to the report, penicillin represented the largest segment.

Penicillin is a widely used class of antibiotics that belongs to the beta-lactam drug class. It works by inhibiting the synthesis of bacterial cell walls that causes cell wall damage and bacterial death. It is considered an essential medicine and is widely available as generic drugs. Apart from this, it is widely used in various healthcare settings, such as hospitals, clinics, and outpatient settings. In addition, the rising utilization of penicillin, as it is effective against various bacterial infections, is contributing to the growth of the market.

Breakup by Spectrum of Activity:

Broad-Spectrum Antibiotics

Narrow-Spectrum Antibiotics

Broad-spectrum antibiotics hold the biggest market share

The report has provided a detailed breakup and analysis of the market based on the spectrum of activity. This includes broad-spectrum antibiotics and narrow-spectrum antibiotics. According to the report, broad-spectrum antibiotics represented the largest segment.

Broad-spectrum antibiotics are a class of antibiotics that exhibit activity against a wide range of bacteria, such as gram-positive and gram-negative bacteria. In line with this, the rising adoption of broader spectrum antibiotics, as they are effective against a broader range of microorganisms compared to narrow-spectrum antibiotics, is bolstering the growth of the market. Apart from this, broad-spectrum antibiotics assist in treating infections when the causative bacteria are unknown or when the infection involves multiple bacterial species. The appropriate use of broad-spectrum antibiotics minimizes the risks of infections in the body.

Breakup by Route of Administration:

Oral

Parenteral

Topical

Others

Parenteral dominates the market segment

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, parenteral, topical, and others. According to the report, parenteral represented the largest segment.

Parenteral antibiotics are administered via routes other than the digestive tract, such as intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. These routes allow for direct delivery of the medication into the bloodstream or deep tissues, bypassing the gastrointestinal system. In addition, parenteral antibiotics provide rapid and predictable drug absorption and immediate therapeutic effect. They are also suitable for patients with compromised gastrointestinal function. Apart from this, it allows for accurate dosing and is particularly beneficial in cases where high drug concentrations are needed or when oral administration is not possible.

Breakup by End User:

Hospitals

Specialty Clinics

Others

Hospitals accounted for the largest market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, specialty clinics, and others. According to the report, hospitals represented the largest segment.

Antibiotics are widely consumed in hospitals due to the increased number of patients staying in this healthcare setting. Antibiotics are administered to patients admitted with severe infections. They are also administered before surgical procedures to reduce the risk of bacterial contamination. In line with this, the rising utilization of antibiotics among individual post-surgical prophylaxis is contributing to the growth of the market. Apart from this, the increasing consumption of antibiotics due to the rising risk of multidrug-resistant infections in hospitals is supporting the growth of the market.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Asia Pacific exhibits a clear dominance, accounting for the largest antibiotics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represented the largest market.

Asia Pacific held the biggest market share due to the improved healthcare infrastructure. In line with this, the growing prevalence of bacterial infections to poor sanitation is contributing to the growth of the market in the Asia Pacific region. Apart from this, the increasing demand for advanced antibiotics that can effectively combat multidrug-resistant bacteria is supporting the growth of the market. Furthermore, the presence of a large number of generic drug manufacturers is propelling the growth of the market in the region.

Competitive Landscape:

Key players in the industry are investing in research and development (R&D) activities to discover and develop new antibiotics and focusing on antibiotic resistance, expanding the spectrum of activity, and improving the efficacy and safety profiles of antibiotics. Apart from this, they are engaging in collaboration with research institutions, academic organizations, and government bodies to leverage their expertise and address the challenges associated with antibiotic development, such as high costs and regulatory compliances. Moreover, antibiotic companies are actively promoting antibiotic stewardship programs that encourage responsible and appropriate use of antibiotics to avoid overdosage and misusage. Furthermore, companies are increasingly conducting clinical trials and adhering to safety and efficacy standards to obtain regulatory approvals for their antibiotics.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Allergan Plc (AbbVie Inc.)

Basilea Pharmaceutica AG

GlaxoSmithKline Plc

Johnson & Johnson

Melinta Therapeutics

Merck & Co. Inc.

Nabriva Therapeutics Plc

Paratek Pharmaceuticals Inc.

Pfizer Inc.

Sanofi SA

Spero Therapeutics

Tetraphase Pharmaceuticals

Recent Developments:

In 2021, Sandoz, a Novartis division, successfully completed the acquisition of GlaxoSmithKline's (GSK) cephalosporin antibiotics business. This acquisition provides them rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets to Sandoz.

In January 2020, Merck & Co. Inc. announced that U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID(R) (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older.

Key Questions Answered in This Report

  • 1. How big is the global antibiotics market?
  • 2. What is the expected growth rate of the global antibiotics market during 2024-2032?
  • 3. What are the key factors driving the global antibiotics market?
  • 4. What has been the impact of COVID-19 on the global antibiotics market?
  • 5. What is the breakup of the global antibiotics market based on the action mechanism?
  • 6. What is the breakup of the global antibiotics market based on the drug class?
  • 7. What is the breakup of the global antibiotics market based on the spectrum of activity?
  • 8. What is the breakup of the global antibiotics market based on the route of administration?
  • 9. What is the breakup of the global antibiotics market based on the end user?
  • 10. What are the key regions in the global antibiotics market?
  • 11. Who are the key players/companies in the global antibiotics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibiotics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Action Mechanism

  • 6.1 Cell Wall Synthesis Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Protein Synthesis Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Synthesis Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 RNA Synthesis Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Mycolic Acid Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cephalosporin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Penicillin
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Fluoroquinolone
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Macrolide
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Carbapenem
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Aminoglycoside
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Spectrum of Activity

  • 8.1 Broad-Spectrum Antibiotics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Narrow-Spectrum Antibiotics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Topical
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Specialty Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Allergan Plc (AbbVie Inc.)
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica AG
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 GlaxoSmithKline Plc
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Johnson & Johnson
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Melinta Therapeutics
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Merck & Co. Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Nabriva Therapeutics Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Paratek Pharmaceuticals Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
    • 16.3.9 Pfizer Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Sanofi SA
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Spero Therapeutics
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
    • 16.3.12 Tetraphase Pharmaceuticals
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antibiotics Market: Major Drivers and Challenges
  • Figure 2: Global: Antibiotics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antibiotics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antibiotics Market: Breakup by Action Mechanism (in %), 2023
  • Figure 5: Global: Antibiotics Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Antibiotics Market: Breakup by Spectrum of Activity (in %), 2023
  • Figure 7: Global: Antibiotics Market: Breakup by Route of Administration (in %), 2023
  • Figure 8: Global: Antibiotics Market: Breakup by End User (in %), 2023
  • Figure 9: Global: Antibiotics Market: Breakup by Region (in %), 2023
  • Figure 10: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Antibiotics (Protein Synthesis Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Antibiotics (Protein Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Antibiotics (DNA Synthesis Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Antibiotics (DNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Antibiotics (RNA Synthesis Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Antibiotics (RNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Antibiotics (Mycolic Acid Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Antibiotics (Mycolic Acid Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Antibiotics (Other Action Mechanisms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Antibiotics (Other Action Mechanisms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Antibiotics (Cephalosporin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Antibiotics (Cephalosporin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Antibiotics (Penicillin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Antibiotics (Penicillin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Antibiotics (Fluoroquinolone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Antibiotics (Fluoroquinolone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Antibiotics (Macrolide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Antibiotics (Macrolide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Antibiotics (Carbapenem) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Antibiotics (Carbapenem) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Antibiotics (Aminoglycoside) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Antibiotics (Aminoglycoside) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Antibiotics (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Antibiotics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Antibiotics (Broad-Spectrum Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Antibiotics (Broad-Spectrum Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Antibiotics (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Antibiotics (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Antibiotics (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Antibiotics (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Global: Antibiotics (Topical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Global: Antibiotics (Topical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Global: Antibiotics (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Antibiotics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Antibiotics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Antibiotics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Global: Antibiotics (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Global: Antibiotics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Global: Antibiotics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Global: Antibiotics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: North America: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: North America: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United States: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United States: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Canada: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Canada: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Asia-Pacific: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Asia-Pacific: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: China: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: China: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Japan: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Japan: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: India: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: India: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: South Korea: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: South Korea: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Australia: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Australia: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Indonesia: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Indonesia: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Europe: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Europe: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Germany: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Germany: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: France: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: France: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: United Kingdom: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: United Kingdom: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Italy: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Italy: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Spain: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Spain: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Russia: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Russia: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Others: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Latin America: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Latin America: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Brazil: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Brazil: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Mexico: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Mexico: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 98: Others: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 99: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 100: Middle East and Africa: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 101: Middle East and Africa: Antibiotics Market: Breakup by Country (in %), 2023
  • Figure 102: Middle East and Africa: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 103: Global: Antibiotics Industry: SWOT Analysis
  • Figure 104: Global: Antibiotics Industry: Value Chain Analysis
  • Figure 105: Global: Antibiotics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibiotics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antibiotics Market Forecast: Breakup by Action Mechanism (in Million US$), 2024-2032
  • Table 3: Global: Antibiotics Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Antibiotics Market Forecast: Breakup by Spectrum of Activity (in Million US$), 2024-2032
  • Table 5: Global: Antibiotics Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 6: Global: Antibiotics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 7: Global: Antibiotics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Antibiotics Market: Competitive Structure
  • Table 9: Global: Antibiotics Market: Key Players